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Abstract: Gaucher disease (GD), the inherited deficiency of the lysosomal enzyme glucocer-
ebrosidase, presents with a wide range of symptoms of varying severity, and primarily affects the 
skeletal, hematologic and nervous systems. To date, the standard of care has included enzyme 
replacement therapy with imiglucerase. Although imiglucerase is highly effective in reversing 
the visceral and hematologic manifestations, skeletal disease is slow to respond, pulmonary 
involvement is relatively resistant, and the CNS involvement is not impacted. Because of the 
recent manufacturing and processing problems, the research and development of alternative 
therapeutics has become more pressing. The divergent phenotypes and the heterogeneity 
involving different organ systems implicates the involvement of several pathological processes 
that include enzyme deficiency, substrate accumulation, protein misfolding, and macrophage 
activation, that differ in each patient with GD. Thus, the therapy should be tailored individually 
in order to target multiple pathways that interplay in GD.
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Introduction
Gaucher disease (GD), the inherited deficiency of the lysosomal enzyme glucocerebro-
sidase ([GC] enzyme commission number EC 3.2.1.45), presents with a wide range 
of symptoms of varying severity, and primarily affects the skeletal, hematologic and 
nervous systems. Clinically, there are three types of GD based upon the presence and 
progression of the neurological symptoms. Absence of central nervous system (CNS) 
involvement is considered mandatory for a diagnosis of the adult form or type 1 GD, 
also known as nonneuronopathic GD. When there is neuronopathic involvement, the 
distinction between infantile, type 2 or juvenile and the type 3 form of GD, is made 
in the basis of age of onset and progression of CNS symptoms. While an intermediate 
phenotype between types 2 and 3 is also described.1
The gene encoding GC (GBA, MIM# 606463) and its homologous pseudogene 
are located on chromosome 1q21.2 To date, more than 250 different GBA mutations, 
including missense, nonsense, insertions or deletions that lead to frameshift or in-frame 
alterations, and splice junction mutations have been identified. Recombination events 
with a highly homologous pseudogene downstream of the GBA locus have also been 
reported.3 Although certain mutations, especially N370S are associated only with 
adult or nonneuronopathic forms, the validity of a phenotype prediction based upon 





results in neuronopathic GD, a milder clinical phenotype 
could be observed with very low residual enzymatic activi-
ties.4 Remarkably, phenotype and disease severity may vary 
among siblings, even in identical twins, and among patients 
carrying same mutations, a wide range of phenotypes and 
residual enzymatic activity are observed.4,5
GC is a membrane-associated lysosomal glycoprotein. 
After synthesis and initial folding at a neutral pH in the 
endoplasmic reticulum, it is targeted to the lysosomes, where 
the acidic pH provides the optimal environment for stable 
folding and function. The majority of GBA mutations lead to 
the synthesis of GC with decreased catalytic function and/or 
stability.6 While it is assumed that disease severity depends 
on residual GC activity, this has been difficult to prove for 
most GBA mutations.7
GC deficiency results in the accumulation of the lipid 
substrate glucosylceramide. Glucosylceramide is the com-
mon intermediate resulting from lysosomal degradation of 
gangliosides and globosides, primarily in cells derived from 
monocyte-macrophage origin. The hallmark “Gaucher cells” 
are glucosylceramide-laden macrophages, observed in many 
organs, although they are predominant in bone marrow, liver 
spleen, and the parenchyma of lymph nodes.8 The accumu-
lation of glucosylceramide causes enlargement of liver and 
spleen. Splenomegaly is associated with hypersplenism 
leading to anemia and thrombocytopenia. Pancytopenia 
is also caused by replacement of the bone marrow. Other 
skeletal manifestations include decreased mineralization, 
pathological fractures, bone pain, avascular necrosis, and 
painful “bone crises”.9 There is primarily radiological evi-
dence of interstitial lung involvement, and on rare occasions 
pulmonary hypertension can occur.10 Additionally in children 
growth failure is also a common feature.11
This review will focus on the mechanisms interplaying 
in GD, and discuss current therapy and others, that are on 
the immediate horizon, that target different pathological 
pathways.
Gaucher disease, the deficiency 
of the lysosomal enzyme 
glucocerebrosidase: recombinant 
enzyme therapy
Human GC is encoded by a single locus (GBA) at chromo-
some 1q21.12 This lysosome-associated glycoprotein has 
497 amino acids, and N-glycosylation at four or five dif-
ferent sites that is essential for its catalytic activity and half 
life.13 In the lysosome, GC catalyzes a two-step reaction 
that requires glycosylation of its active site by the substrate, 
followed by the release of beta-glucose by deglucoslation.14 
To enhance in vitro activity, negatively charged phospholip-
ids, and a naturally occurring 80 amino acid protein, saposin 
C are required.15 While there is evidence that GC physically 
interacts with saposin C, the exact mechanism of saposin 
C-mediated GC activation is not known.16
The resolution of the X-ray crystal structure of human GC, 
followed by the demonstration of a nonreversible inhibitor, 
conduritol β-epoxide (CBE) bound GC structure helped to 
understand the effects of the tertiary structure on catalytic func-
tion, and spatial relationship of GBA mutations with the active 
site. The 3D structure with the CBE had confirmed E340 as 
the nucleophile and E235 as the acid-base catalyst.17 Although 
few mutations that are associated with a severe phenotype 
occur near the catalytic site, the majority of GBA variants are 
spread through the domains of the protein. However, there is 
no clear relationship between the position of GBA variants in 
the 3D structure and the disease severity.18 While the crystal 
structure is not available for GBA mutants; among the common 
mutations L444, which is mutated to proline or arginine, is 
located at the hydrophobic core of the protein, and is predicted 
to produce unstable protein.19 Whereas the mutation N370S 
has been suggested to flank the active site, and alter interaction 
with saposin C and anionic phospholipid membranes.20
In 1964, De Duve introduced the concept of replacing 
the deficiency of a lysosomal enzyme.21 Proof of the general 
principles of enzyme replacement therapy (ERT) was devel-
oped in a model system using cocultivation of fibroblasts 
from patients with different types of mucopolysaccaharidosis, 
that corrected the enzymatic deficiency.22 Early attempts to 
correct the enzymatic deficiency in 1970’s revealed the criti-
cal importance of N-linked oligosaccharide chain stability 
of the lysosomal enzymes, and the importance of cell-type 
specific uptake in different diseases. The recognition signal 
was initially identified as mannose, and in vivo clearance of 
the lysosomal enzymes from plasma was found to be mediated 
by mannose receptors of the reticuloendothelial system. ERT 
quickly advanced in GD, where macrophages were regarded 
as the primary source for the stored abnormal lipid.23 The first 
enzyme preparation purified from placental tissue did not yield 
any significant clinical response, although the total amount of 
stored lipid was shown to be reduced in liver samples.24 The 
placental enzyme that contained complex N-linked glycans 
was largely taken up by the asialoglycoprotein receptors 
present on hepatocytes.25 Further modification of N-linked 
oligosaccharide terminals to remove sialic acid residues, that 
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internalization of the enzyme by the Gaucher macrophages.26 
This modified high-mannose form of enzyme was readily rec-
ognized by mannose receptors abundant on the macrophages.27 
The first placental derived enzyme product alglucerase (Cere-
dase®; Genzyme Inc, Cambridge, MA, USA) was developed 
based on this principle, and was tested successfully on 12 
patients with type 1 GD with improvements in hematological 
parameters, and the reduction in organ volumes.28 This was 
followed by two trials on 25 patients with imiglucerase (Cer-
ezyme®; Genzyme Inc), a recombinant form of human GC, 
which differs from native GC with a substitution of histidine 
instead of arginine at position 495. Until the clinical use of 
ERT in 1990’s, the treatment of GD consisted only of pallia-
tive measures such as splenectomy and hip replacement. The 
development of ERT for GD is considered to be a triumph of 
translational medicine. ERT is a safe and well tolerated treat-
ment modality with only rare side effects. Currently, there are 
more than 5000 patients with GD that are successfully being 
treated with imiglucerase.
In vivo, recombinant GC shows high-affinity targeting 
to the macrophages.27 In humans and mice, imiglucerase 
has been shown to exhibit similar postinjection distribution 
patterns. The uptake of the human enzyme is primarily by 
the reticuloendothelial cells of the liver and spleen. In mice, 
post-injection enzymatic activity peaks at about 20 minutes in 
the liver and spleen, followed by a biphasic decrease, with a 
half-life around 40–60 minutes and 12–14 hours respectively. 
While in bone marrow, the maximal enzymatic activity is mea-
sured at 40–60 minutes.29 The uptake and tissue distribution 
of radio-labeled recombinant enzyme after a bolus injection 
was followed in patients with type 1 GD. About half of the 
radio-labeled enzyme was rapidly cleared from blood with a 
half-life less than five minutes. 30% of the injected dose was 
taken up immediately by the liver, about 15% by the spleen, 
and the bone marrow, where the half-life was over 14 hours. 
The remainder was cleared slowly with a half-life of between 
34–42 hours. When the enzyme was administered at a higher 
dose, the receptor-mediated uptake was saturated, and the 
clearance half-life of tracer enzyme was prolonged.30
During the original clinical trial, imiglucerase was admin-
istered at a dose of 60 IU/kg every two weeks.28 There is a 
dose-dependent improvement in hematological and visceral 
parameters with alglucerase/imiglucerase. Patients with type 
1 GD treated with doses more than 48 IU/kg, every two weeks, 
were suggested to have better clinical responses.31 However, 
lower dose higher frequency or higher doses administered at 
less frequent intervals could provide similar clinical efficacy. 
The therapeutic threshold for macrophage-targeted GC appears 
to be 10–15 IU/kg every 2 weeks. Although high dose therapy 
provides a faster clinical response, and should be considered for 
patients with a more aggressive disease, the initiation of ERT at 
a lower dose has also led to an improvement in all nonskeletal 
manifestations of GD. The effects of initiating ERT at a high 
dose, followed by progressive dose reductions, were compared 
with starting the therapy at a low dose only. In patients who 
were started on high-dose ERT, hemoglobin, acid phosphatase, 
and organ volume improved or remained unchanged at the end 
of each dose reduction, although the platelet count decreased 
when the dose of enzyme was reduced to 15 IU/kg. While 
in the treatment group that started at the minimal dose, the 
manifestations were similarly well controlled.32 In another 
study, there were no significant differences in clinical outcome 
when the recombinant enzyme was given at different dosing 
schedules including: 15 IU/kg once fortnightly or 2.5 IU/kg 
thrice weekly.34 Thus, smaller total doses of recombinant GC, 
administered frequently may have significant financial ben-
efits, and could be considered in patients with stable type 1 
GD.33 Similarly, even lower doses (7.5 IU/kg every two weeks) 
established good visceral and hematological response in adult 
patients with mild to moderate skeletal involvement.35 Despite 
some rare reports of treatment failures in patients with a higher 
disease burden, ERT administered every four weeks, was 
shown to be effective in most adult type 1 GD patients with 
stable and minimal disease.36,37 Currently, the recommendations 
for commencing imiglucerase treatment and subsequent dose 
adjustments are based on regular assessment and monitoring. 
Then, the maintenance of defined therapeutic goals, that include 
hematopoietic reconstitution, the reduction of liver and spleen 
volumes, together with the stabilization or improvement in 
skeletal findings is achieved on an individualized regimen.38 
While tailoring therapy for each individual patient, several 
other parameters including the cost, and impact to the life style 
should also be taken into consideration.
In individuals with nonneuronopathic GD presentation 
during childhood years suggests a more severe phenotype. 
However many patients who are diagnosed in large-scale 
screenings, are mildly affected and may not require treatment. 
In a retrospective study, 56 children with nonneuronopathic 
GD, were followed up to 9 years, and only massive spleno-
megaly and growth retardation were found to be indications 
for ERT.39 In symptomatic children, however, early interven-
tion aims to prevent the development of complications, and 
ensure normal growth and development through adolescence. 
In a large international cohort of children with GD type 1 on 
ERT, the longitudinal data supports the normalization of most 





and mean bone mineral density z scores.40 Several consensus 
statements for treatment and monitoring of children with 
GD, include regular assessments, and individualized dose 
adjustments based on clinical response.41,42 Although a lower 
maintenance dose of 30–35 IU/kg/month may be effective in 
most pediatric patients, more severely affected ones, especially 
L444P/L444P homozygotes, may require a higher maintenance 
dosage.43 In addition to clinical parameters, the follow up in 
this age group should also include evaluation of psychosocial, 
functional status and quality-of-life assessments.44
Although imiglucerase is highly effective in reversing the 
visceral and hematologic manifestations, skeletal disease is 
slow to respond, pulmonary involvement is relatively resistant 
to the enzyme, and the CNS involvement is not impacted by 
ERT. Some patients with type 1 GD even may experience 
ongoing bone disease, despite increasing doses of ERT. 
In such patients the ERT dose should be adjusted in order 
to maintain adequate visceral control, although alternative 
strategies including the addition of bisphosphonates could be 
explored.45 There is great heterogeneity in response to ERT in 
patients with GD and symptomatic lung involvement. Clini-
cally, some patients benefit significantly from enzyme therapy. 
However, pulmonary function or radiological findings do not 
usually normalize, despite the correction of hematological 
parameters and the reduction in organ volumes.10 Although 
worsening pulmonary pressures have been reported after the 
introduction of ERT, pulmonary hypertension is associated 
either with poor compliance, or the lack of ERT.46 An emerg-
ing concern has been whether ERT could prevent the progres-
sion of the neurological disease in neuronopathic GD. The 
guidelines for the management of the neuronopathic forms of 
GD were recently revised. In particular, the role of high-dose 
ERT (120 IU/kg of body weight every 2 weeks) was analyzed. 
In patients receiving high-dose ERT, there was a consistent 
progression of brain stem findings, concomitant with the 
deterioration of auditory brain stem responses.47 Although 
high dose ERT may be required to control severe systemic 
symptoms, it does not stabilize neurological symptoms, and 
thus, is not recommended in neuronopathic GD.48,49
Other recombinant glucocerebrosidases, recently 
approved by the FDA or pending approval, include vela-
glucerase alpha (Shire HGT, Cambridge, MA, USA) and 
taliglucerase alpha (Protalix Biotherapeutics, Carmiel, 
Israel; Pfizer, NY, USA). Both have successfully completed 
phase III trials, and proven to be safe and clinically efficient. 
Although considered as biosimilars, the new recombinant 
GCs are not generic proteins, they are produced as novel 
biologicals. Imiglucerase is expressed in Chinese hamster 
ovary cells, where as taliglucerase is produced in transgenic 
carrot cells. In contrast to imiglucerase and taliglucerase, 
velaglucerase alpha, the gene-activated human GC, contains 
the native human enzyme sequence. On X-ray crystallogra-
phy, all three glucocerebrosidases consist of three domains, 
and the active site is located in domain III, and E340 and 
E235 are the catalytic residues.50 Taliglucerase alpha dem-
onstrates a high degree of homology to imiglucerase in 
its high-resolution three-dimensional structure, and has a 
bioactivity similar to imiglucerase.51 In clinical trials, vela-
glucerase displayed pharmacokinetic properties suggesting 
that the tissue distribution is linear to the doses administered. 
In patients, the serum concentration increased linearly with 
increasing doses from 15 IU/kg to 60 IU/kg, and the maxi-
mum serum concentration was recorded at the end of the first 
hour of the infusion.52 Although velaglucerase has a specific 
activity comparable with imiglucerase, the cellular uptake is 
suggested to be more efficient due to differences in glycosy-
lation. Imiglucerase contains a chitobiose tri-mannosyl core 
glycan with fucosylation, while velaglucerase predominantly 
displays high-mannose type glycans with nine mannose units. 
The differences in glycosylation are suggested to affect bet-
ter internalization into human macrophages.50 Taliglucerase 
is targeted to the storage vacuoles using a plant-specific 
C-terminal sorting signal, that naturally contains terminal 
mannose residues in its complex glycans. Thus, taliglucerase 
does not require exposure of mannose residues in vitro, which 
is a requirement for the production of other recombinant 
GCs.53 Nevertheless, higher number of mannose residues may 
result in increased immunogenicity due to the presentation 
of nonmammalian glycans.54 However, there have been no 
clinical adverse effects, nor increased frequency of neutral-
izing antibodies associated with taliglucerase during safety 
and pharmacokinetics studies.54 Recently, there has been 
serious problems in the manufacturing and processing of 
imiglucerase, and availability of alternative therapeutics has 
become more pressing than ever. Having different enzymes 
for therapeutic use will provide an opportunity to re-evaluate 
indications and initiation of ERT, management of nonre-
sponders, and a cost–benefit maintenance therapy.
Gaucher disease, a storage disorder 
of the lysosomes: substrate 
reduction therapy (SRT)
The pathophysiology of lysosomal storage diseases is 
not completely understood and there is no doubt that 
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secondary biochemical and cellular events, is one of the 
  primary the pathogenic factors. In GD, glucosylceramide 
accumulates in the lysosomes, it is not known whether the 
cellular pathology is related to the lysosomal dysfunction 
secondary to storage, or whether glucosylceramide escapes 
from the lysosome and interacts with other organelles. In 
macrophages, for example, glucosylceramide accumulation is 
suggested to cause enhanced phagocytic activity.55 Glucosyl-
ceramide accumulates in tissues, and is elevated in the plasma 
of patients with GD, the amount is not significant.56 While 
ERT is aimed to remove the accumulation of storage material 
within the lysosome, SRT targets the biosynthetic cycle to 
partially reduce the load of substrate influx to the lysosome, 
which is already catabolically compromised. Miglustat (Zav-
esca®; Actelion Ltd, Basel Switzerland) is an imino sugar 
that reversibly inhibits the critical step in glycosphingolipid 
synthesis, and has been approved as the first oral SRT agent. 
During the trials, there was a significant reduction in organ 
volumes, although the improvement in hematological param-
eters was less significant, and thus, miglustat is recommended 
primarily for adult patients with GD type1, who are unable 
or unwilling to be on ERT.57 However, significant side effects 
such as loose stools, tremor and peripheral neuropathy have 
limited its therapeutic use.58 Currently attempts are ongoing 
to develop other glucosylceramide inhibitors, and a phase III 
clinical trial is being conducted to evaluate the efficacy, 
safety, and pharmacokinetics of a novel SRT molecule in 
adult patients with GD type 1 (ClinicalTrials.gov identifier: 
NCT00891202). Unlike recombinant enzymes, SRT agents 
are small molecules that can cross the blood-brain barrier.59 
Although improved pulmonary function, and a significant 
decrease in chitotriosidase levels have been observed in 
patients with GD type 3, miglustat unfortunately, does not 
appear to have any significant benefits on the neurological 
manifestations of GD.60
Glycosphingolipids affect a variety of cellular functions, 
and long term SRT may theoretically alter several pathways 
in the cell, and therefore, should be approached with great 
clinical care.61
Gaucher disease, a protein 
misfolding disorder: pharmacological 
chaperones and enzyme 
enhancement therapy (EET)
The majority of GBA mutations are missense, leading 
to the synthesis of GC with decreased catalytic function 
and/or stability.3 At the cellular level, missense mutations 
can result in altered processing or a conformational change 
in the mutant protein leading to a toxic gain-of-function.62,63 
Protein misfolding contributes to the pathophysiology of 
several genetic and sporadic diseases. A prime example for 
proteinopathies is the adult-onset neurodegenerative diseases, 
where diverse molecular mechanisms result in the abnormal 
accumulation of proteins in the nervous system. Parkinson 
disease is the prototype adult-onset neurodegenerative dis-
order, characterized by the abnormal accumulation alpha-
synuclein that results in intraneuronal aggregates and cell 
death.64 Clinical, genetic and neuropathologic observations 
have shown that GBA mutations constitute a risk factor for 
the development of parkinsonian manifestations, thus leading 
to the hypothesis that protein misfolding may play a role in 
the phenotypes associated with GD.65–67
“Pharmacological chaperones” are small molecules that 
bind to misfolded proteins, and assist their correct refold-
ing and/or maturation. Chaperone or EET is an attractive 
approach because of its potential for simple oral administra-
tion, penetration of the blood–brain barrier, and its low cost. 
EET has been proposed for a number of lysosomal storage 
disorders, including GD, Sandhoff, Fabry, and Tay-Sachs 
diseases.68,69 The mechanism of action for these compounds 
is competitive binding to the active site of the mutant enzyme, 
facilitating proper folding and trafficking to the lysosome, 
where endogenous substrate displaces the chaperone and 
enzyme activity is restored.70 Most chaperones studied to 
date are enzyme inhibitors in the structural class of imino 
sugars or similar analogs of the natural substrate, glucosyl-
ceramide.71 Imino sugars have been shown to increase the 
cellular activity of the N370S mutant form of GC, as well as 
the wild-type enzyme.72 In cell based systems, where fibro-
blasts from patients are cultured with the chemical chaperone 
N-nonyl-deoxynojirimycin, the enzymatic activity of the GC 
variant, N370S, is increased. Similarly G202R, a GC variant 
retained in the endoplasmic reticulum, is also shown to be 
amenable to chemical chaperoning.73 However, imino sugar 
derivatives are nonspecific and have relatively short half-lives 
in cells, and these molecules can inhibit other glycolipid and 
glycoprotein processing enzymes.74 Several studies have 
demonstrated that isofagomine (IFG), an imino sugar that 
binds to the active site, enhanced the folding, transport, and 
stability of several GC variants, including L444P.75 IFG was 
found to have little or no inhibitory activity against other 
glucosidases, and further treatment of wild type fibroblasts 
with high doses did not alter the processing of newly synthe-
sized N-linked oligosaccharides.76 These findings supported 





agent in GD. Despite promising in vivo results, and safety 
data (Clinical Trials.gov Identifier: NCT00433147), clini-
cally meaningful improvements in key measures of the 
disease were not adequate. There are no plans to advance 
this chaperone further into a phase III trial. In addition to 
imino sugars, calcium channel blockers are suggested to 
act as pharmacologic chaperones through altered calcium 
homeostasis, and are shown to partially restore mutant GC 
activity.77 While diltiazem exhibited the properties of a 
pharmacological chaperone at neutral pH, of the endoplas-
mic reticulum in cell-based systems, in animal studies these 
effects were minor.78,79
Screening large compound libraries by quantitative 
high-throughput screening (qHTS) provides comprehensive 
information on the potency, efficacy, and structure-activity 
relationships of active compounds, facilitating identification of 
leads for medicinal chemistry optimization. qHTS was used to 
rapidly identify different nonsugar GC inhibitors.80 Similarly, 
screening a library of FDA-approved drugs using a thermal 
denaturation assay identified Ambroxol (a drug used to treat 
airway mucus hypersecretion and hyaline membrane disease 
in newborns) as a pH-dependent, mixed-type inhibitor of GC. 
Ambroxol demonstrates the characteristics of an EET agent 
through its interaction with both active and nonactive sites, and 
may have the potential to move towards clinical trials.81
Although EET is promising to treat CNS manifestations, 
in vitro studies has shown that pharmacological chaperones 
are mostly mutation specific, and they may not be suitable 
for every patient with GD. Long-term clinical trials are 
required to test the in vivo effects of different chaperones on 
the specific disease pathology that could be associated with 
protein misfolding.
Gaucher disease, a macrophage 
disorder
GD was described more than a century ago by the identifica-
tion of lipid engorged macrophages, referred to as “Gaucher 
cells”, were periodic acid Schiff-positive cells with wrinkled-
tissue paper like appearance. GD has been regarded primar-
ily as a macrophage disorder; however, current knowledge 
renders this classification too simplistic. Gaucher cells are not 
inert storage cells, they are metabolically active and secrete 
various proteins. In the plasma of patients with GD, the levels 
of macrophage/monocyte activation markers such as soluble 
CD14 and CD 163 are elevated.82 Gaucher cells strongly 
express markers of alternative activation, such as interleu-
kin-1 antagonist and CCL18, which are anti-inflammatory 
molecules.83 Other biochemical correlates of GD represent 
hydrolases, localized to storage cells and/or surrounding 
macrophages, such as tartrate-resistant acid phosphatase and 
angiotensin-converting enzyme.84,85 These biomarkers, how-
ever, are nonspecific, and are altered in a number of disorders 
that affect the reticuloendothelial system. Furthermore, the 
overlap between the levels of hydrolases between patients 
with GD and healthy controls restrict their clinical use.86 
In the plasma of symptomatic GD patients, biochemical 
investigations demonstrated a more than 1000-fold increase 
of a class of chitinases, named “chitotriosidase”. Chitotri-
osidase originates from macrophages, and stored lipid is the 
major inducer.87 Macrophages are also the primary source 
for another cytokine, CCL18, which has been found to be 
elevated in GD.88 Both these surrogate markers are not organ 
specific, although they may reflect overall disease burden, 
and respond to therapeutic response.89 While the exact 
contribution of chitotriosidase and CCL18 to the disease 
pathophysiology remains to be elucidated, the pulmonary, 
skeletal and immune system involvement in GD may have a 
closer association with the activation and release of different 
cytokines from the macrophage-monocyte system. During the 
chronic inflammatory process, as is observed in some patients 
with GD, the balance between bone formation and resorption 
is skewed toward osteoclast-mediated bone resorption, which 
may explain osteopenia commonly observed in patients with 
GD.90–92 Macrophage activation is the common denominator 
in multiple disorders, characterized by radiological evidence 
of interstitial pulmonary involvement. While chitotriosidase 
is one of the established biomarkers for GD, it has been 
recently used as an indicator in alveolar lung diseases, such 
as sarcoidosis and miliary tuberculosis.93,94 Chitotriosidase 
levels are shown to be significantly higher in patients with 
idiopathic interstitial lung disease.95
Surrogate markers in GD serve only as indicators of 
macrophage activation, and should not be used as diagnostic 
tools. Macrophages participate in the autoregulatory loop of 
the inflammatory process, and produce a wide range of bio-
logically active molecules participating in both the beneficial 
and detrimental outcomes in inflammation. The inflammatory 
component in GD may play a role in the development and pro-
gression of bone, pulmonary and neurological complications. 
Therapeutic interventions that target macrophages and their 
products may open new avenues in the treatment of GD.
Conclusion
Although GD is considered to be a “simple Mendelian disorder”, 
divergent phenotypes and the heterogeneity involvement of dif-
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of different pathological pathways. Thus the optimal therapeutic 
expectations may differ in each patient with GD. Despite better 
tissue penetration and alternative mechanisms of action of novel 
therapeutics what is potentially achievable and what is likely to 
remain irreversible in GD manifestations will be contingent upon 
multiple factors such as genetic and environmental modifiers. 
The bone and secondary neurological manifestations in adult-
onset GD may serve as examples for some perceived limitations 
of clinical management in GD. Although the ultimate aim is to 
treat all skeletal manifestations, such as the reversal of osteopenia 
and to prevent and treat bone crises, a clinician who follows a 
number of patients with GD will be aware that some patients 
will progressively lose bone mineral density or develop new 
bone lesions, despite a maximum dose ERT, diet supplements 
or weight-bearing exercises. The establishment of the association 
between GBA mutations and the development of parkinsonian 
manifestations have brought new challenges for both the clini-
cian and researchers. There are several lines of evidence that 
suggest there is an association between GBA mutations and 
development of Parkinson disease pathology.96,97 Although the 
risk of Parkinson disease is suggested to be increased, especially 
among individuals carrying “severe” GBA mutations, the pen-
etrance and again the role of modifiers are not known for each 
GBA alteration.98 Furthermore, 99% of individuals carrying GBA 
mutations either in hetero- or homozygote states will not develop 
parkinsonian manifestations, limiting the genetic counseling even 
in “at risk” individuals in families with more than one person 
affected. The current recommended therapy for GBA-associated 
parkinsonism is limited to the standard parkinsonian therapy, 
when the symptoms are L-dopa responsive, and testing for GBA 
mutations remains an academic endeavor more than that of a risk 
and prognostic determinant.
The future of the treatment of GD will include an indi-
vidualized approach, employing a combination of therapies 
that can address the effects of enzyme deficiency, storage of 
abnormal lipid substrate resulting in lysosomal dysfunction, 
protein misfolding and the inflammatory processes.
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